ReNeuron Signs Cell Manufacturing Contract for Completion of Stroke Clinical Trial; Recruitment of Patients for Remaining Two Dose Cohorts on Track ReNeuron announced that it signed a new cell manufacturing contract with Angel Biotechnology Holdings plc to perform GMP drug product manufacturing services to serve the remaining part of the PISCES Phase I clinical trial of ReNeuron’s ReN001 stem cell therapy for stroke. [ReNeuron Group plc] Press Release Fibrocell Science, Inc. Announces Exclusive License Agreement with UCLA on Dermal Cell Research to Advance the Development of Personalized Cell Therapies Fibrocell Science, Inc. announced that it has signed an exclusive license agreement with The Regents of the University of California, under which it acquired the rights to commercially apply discoveries resulting from the scientific collaboration between the University of California, Los Angeles (UCLA) and Fibrocell Science, Inc. [Fibrocell Science, Inc.] Press Release Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell Therapies Fibrocell Science, Inc. announced the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives Initiative in collaboration with researchers from a number of different universities across the U.S. [Fibrocell Science, Inc.] Press Release Groundbreaking Alzheimer’s Disease Prevention Trial Announced In collaboration with the National Institutes of Health, Banner Alzheimer’s Institute, University of Antioquia in Colombia and Genentech announced the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. [Banner Alzheimer’s Institute] Press Release
Research Investment in Bone Marrow Failure Disease Two research projects focused on a bone marrow failure disease recently received funding from the Aplastic Anemia and Myelodysplasia Association of Canada and the Canadian Institutes of Health Research. [Canadian Institutes of Health Research] Press Release Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s Lead Product StemEx® for Leukemia and Lymphoma The financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers who can be cured by bone marrow transplantation but do not have a matched bone marrow donor. [Gamida Cell] Press Release
Kyoto University Granted Its Third iPSC Patent in the U.S. Kyoto University was granted its third patent associated with the method to generate induced pluripotent stem cells (iPSCs) by the United States Patent and Trademark Office, following its first and second ones granted last year. [Center for iPS Cell Research and Application, Kyoto University] Press Release World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal Osiris Therapeutics Inc. announced it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. [Osiris Therapeutics Inc.] Press Release Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington’s and Parkinson’s Diseases Intellect Neurosciences, Inc. announced it has filed three new patent applications with the United States Patent and Trademark Office, which expand the Company’s immunotherapy pipeline. [Intellect Neurosciences, Inc.] Press Release Northwest Bio Provides Update on DCVax®-L Brain Cancer Trial Northwest Biotherapeutics announced that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme. [Northwest Biotherapeutics, Inc.] Press Release Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial Juventas Therapeutics reported that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia (CLI). [PR Newswire] Press Release |